Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuhei Hige

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Carcinogenesis|October 17, 2013
Heat shock factor 1 accelerates hepatocellular carcinoma development by activating nuclear factor-κB/mitogen-activated protein kinaseMakoto Chuma, Naoya Sakamoto, Akira Nakai, et al.
Journal of Clinical Medicine|February 26, 2025
Real-World Setting of Efficacy and Safety of 3 Years of Rifaximin Administration in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective StudyHideto Kawaratani, Tadashi Namisaki, Yasuteru Kondo, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 23, 2011
Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis BAkihiro Matsumoto, Eiji Tanaka, Yoshiyuki Suzuki, et al.
Hepatology (Baltimore, Md.)|April 27, 2012
LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patientsKiyoaki Ito, Atsushi Kuno, Yuzuru Ikehara, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 1, 2010
Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis CShuichi Kaneko, Michio Sata, Tatsuya Ide, et al.
Liver Cancer|June 24, 2026
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup AnalysisMasatoshi Kudo, Atsushi Hiraoka, Kazushi Numata, et al.
Journal of Gastroenterology|October 15, 2020
PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradicationDaiki Miki, Tomoyuki Akita, Akemi Kurisu, et al.
Journal of Medical Virology|March 2, 2011
Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2bNaoya Sakamoto, Mina Nakagawa, Yasuhito Tanaka, et al.
Journal of Clinical Microbiology|March 20, 2009
Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype AKentaro Matsuura, Yasuhito Tanaka, Shuhei Hige, et al.
Human Molecular Genetics|June 11, 2011
Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis CYasuhito Tanaka, Masayuki Kurosaki, Nao Nishida, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Carcinogenesis|October 17, 2013
Heat shock factor 1 accelerates hepatocellular carcinoma development by activating nuclear factor-κB/mitogen-activated protein kinaseMakoto Chuma, Naoya Sakamoto, Akira Nakai, et al.
Journal of Clinical Medicine|February 26, 2025
Real-World Setting of Efficacy and Safety of 3 Years of Rifaximin Administration in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective StudyHideto Kawaratani, Tadashi Namisaki, Yasuteru Kondo, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 23, 2011
Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis BAkihiro Matsumoto, Eiji Tanaka, Yoshiyuki Suzuki, et al.
Hepatology (Baltimore, Md.)|April 27, 2012
LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patientsKiyoaki Ito, Atsushi Kuno, Yuzuru Ikehara, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 1, 2010
Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis CShuichi Kaneko, Michio Sata, Tatsuya Ide, et al.
Liver Cancer|June 24, 2026
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup AnalysisMasatoshi Kudo, Atsushi Hiraoka, Kazushi Numata, et al.
Journal of Gastroenterology|October 15, 2020
PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradicationDaiki Miki, Tomoyuki Akita, Akemi Kurisu, et al.
Journal of Medical Virology|March 2, 2011
Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2bNaoya Sakamoto, Mina Nakagawa, Yasuhito Tanaka, et al.
Journal of Clinical Microbiology|March 20, 2009
Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype AKentaro Matsuura, Yasuhito Tanaka, Shuhei Hige, et al.
Human Molecular Genetics|June 11, 2011
Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis CYasuhito Tanaka, Masayuki Kurosaki, Nao Nishida, et al.
Pageof 8